Poor compliance with 5-ASA therapy in patients with gastrointestinal disorders increases the burden on healthcare services: a retrospective survey in Maryland, USA

Systematic review: impact of non‐adherence to 5‐aminosalicylic acid products on the frequency and cost of ulcerative colitis flares

“…Only the study by Kane et al. 38, 39 has assessed this topic finding that adherence was associated with lower total medical costs despite higher medication costs. This finding is not surprising as advocates of value‐based insurance designs 40, 41 have shown that high medication co‐pays can result in poor adherence and net increases in medical costs in diabetes.…”

“…Our systematic review highlights the dearth of economic data about the impact of non-adherence on UC flares and this is another topic that should be assessed within larger maintenance studies that examine the relationship between adherence and disease activity. Only the study by Kane et al 38,39 has assessed this topic finding that adherence was associated with lower total medical costs despite higher medication costs. This finding is not surprising as advocates of value-based insurance designs 40,41 have shown that high medication co-pays can result in poor adherence and net increases in medical costs in diabetes.…”

“…Only one study focused on the net costs of non-adherence in UC patients being treated with 5-ASA medications. Kane et al 38,39 performed a retrospective analysis of the Maryland CareFirst Blue Cross Blue Shield (BCBS) database for the years 2002-2004 to determine the association between 5-ASA adherence and health care costs. Subjects were included if they had an ICD-9 diagnosis of 556 (UC) and were continuously enrolled in the insurance plan throughout the study period.…”